Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline

详细信息    查看全文

• 作者：A. Prica^&lowast ; ; F. Baldassarre^&dagger ; ; ^{baldasf@mcmaster.ca} ; ^{ccopgi@mcmaster.ca} ; L.K. Hicks^&Dagger ; ; K. Imrie^§ ; ; T. Kouroukis^¶ ; ; M. Cheung^§ ; ; the Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care
• 关键词：Chronic lymphocytic leukaemia ; guideline ; lymphoma ; rituximab ; systematic review
• 刊名：Clinical Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：29
• 期：1
• 页码：e13-e28
• 全文大小：920 K
• 卷排序：29

文摘

Rituximab leads to clinically important benefits in progression-free survival or overall survival in the following settings: Addition to combination chemotherapy for initial treatment of aggressive B-cell lymphomas. Addition to combination chemotherapy for initial and subsequent treatment of follicular lymphoma and other indolent B-cell lymphomas. Use as maintenance in patients with indolent B-cell lymphomas who have responded to chemo-immunotherapy. Addition to fludarabine-based chemotherapy or chlorambucil for initial treatment of chronic lymphocytic leukaemia.